Ovestin0.1%

Ovestin is a weak, short-acting natural estrogen used mainly by the vaginal route, and in some markets orally, for the following indications:

Established / Approved uses

• Vaginal (topical) use: Treatment of urogenital symptoms of estrogen deficiency in postmenopausal women, including vaginal dryness, itching, burning, and painful intercourse (dyspareunia) caused by vaginal atrophy.
• Preparation before gynaecological surgery or procedures: Short-course use to improve vaginal epithelial thickness before vaginal surgery or before taking a cervical (Pap) smear in atrophic tissue.
• Oral use (where marketed): Atrophy of the lower urogenital tract related to estrogen deficiency, and relief of climacteric (menopausal) vaginal complaints, as part of individualized hormone therapy.

Guideline-supported / adjunct uses

• Reduction of recurrent urinary tract infections in postmenopausal women that are related to urogenital atrophy, used as an adjunct alongside standard urological care.

Uses with limited/mixed evidence (off-label or adjunct)

• Cervical ripening: Ovestin has been used off-label in obstetric practice to assist cervical ripening before induction of labour; evidence is limited and this is not a primary approved indication.
• Infertility due to cervical mucus hostility: Low-dose oral Ovestin has been used as an adjunct in selected infertility protocols to improve cervical mucus quality, under specialist supervision.

Ovestin is not indicated for prevention of cardiovascular disease or dementia, and its use should be individualized based on symptoms, risk factors, and physician assessment.

Estriol is available in the following strengths and dosage forms (formulation availability varies by market):

• Vaginal cream containing Estriol 0.1% w/w (approximately 0.5 mg Estriol per applicator dose)
• Oral tablets containing Estriol 1 mg

Ovestin is one of the three major naturally occurring endogenous estrogens (along with estradiol and estrone). It is the weakest and shortest-acting of the three, with low binding affinity for estrogen receptors compared with estradiol.

Because of its short duration of action and predominantly local effect when applied vaginally, Ovestin is widely used as a low-systemic-exposure option to treat vaginal and urinary symptoms of menopause, while oral formulations are used where systemic estrogenic effect is desired for climacteric symptoms or selected fertility indications.

Estrogen; topical/systemic hormone replacement agent used for urogenital atrophy (Ovestin is a natural, weak, short-acting estrogen).

Mechanism of action: Estriol acts as an agonist at estrogen receptors ERα and ERβ, though with substantially lower receptor binding affinity than estradiol. This weak, short-acting agonist activity is sufficient to restore the vaginal and urethral epithelium, increase vaginal blood flow and lubrication, and normalize vaginal pH and flora, which underlies its benefit in urogenital atrophy.

Pharmacokinetics: Estriol is absorbed from the vagina and gastrointestinal tract. It is metabolized mainly by conjugation (glucuronidation and sulfation) in the liver and excreted chiefly in urine. Its affinity for sex hormone-binding globulin is low, and it does not accumulate in tissue estrogen receptors for as long as estradiol, which explains its short duration of biological action and requirement for more frequent dosing.

Vaginal administration produces predominantly local effects on the genital epithelium with comparatively low systemic absorption relative to oral or systemic estrogen products, although some systemic absorption still occurs, particularly with prolonged or high-dose use.

Vaginal cream: Wash hands before use. Fill the applicator to the prescribed mark. Lie down, insert the applicator gently and deeply into the vagina, and slowly push the plunger to deposit the cream. Use preferably at bedtime. Wash the applicator with mild soap and water after use.

Oral tablets: Swallow the tablet whole with water. The total daily dose of Ovestin is usually taken as a single dose, with or without food, at approximately the same time each day.

Do not increase the dose or frequency of Ovestin beyond what is prescribed.

The following interactions with Ovestin are clinically relevant:

• Hepatic enzyme-inducing drugs (e.g., rifampicin, phenytoin, carbamazepine, barbiturates, and herbal products such as St. John's Wort) can increase the metabolism of Ovestin, reducing its effectiveness; alternative or additional measures may be needed.
• Ciclosporin: Ovestin and other estrogens may increase circulating ciclosporin levels, raising the risk of ciclosporin toxicity; monitoring is advised with combined use.
• Thyroid hormone replacement: Estrogens including Ovestin can increase thyroid-binding globulin, potentially altering thyroid hormone requirements in patients on levothyroxine; thyroid function should be monitored.
• Oral anticoagulants: Estrogenic compounds may alter the effect of oral anticoagulants; closer monitoring of coagulation parameters is advisable when Ovestin is co-administered.

Because systemic absorption of vaginal Ovestin is comparatively low, clinically significant interactions are less likely with vaginal use than with oral use, but cannot be excluded, especially with prolonged or high-dose therapy.

Common side effects of Ovestin include:

• Breast tenderness or enlargement
• Headache
• Nausea
• Vaginal discharge, local irritation, or itching (with vaginal use)
• Irregular vaginal spotting or breakthrough bleeding
• Fluid retention or mild swelling

Less common but serious effects (more relevant with prolonged or systemic/oral use) include venous thromboembolism, gallbladder disease, changes in liver function, and, rarely, endometrial hyperplasia with unopposed long-term use. Patients should seek urgent medical attention for calf pain/swelling, chest pain, sudden breathlessness, severe headache, visual disturbance, or jaundice.

Pregnancy: Ovestin is contraindicated in known or suspected pregnancy. It should not be used during pregnancy; if pregnancy occurs during treatment, Ovestin must be discontinued immediately and the patient should consult her physician.

Lactation: Ovestin is generally not recommended during breastfeeding, as estrogens can reduce milk quantity and quality, and small amounts may pass into breast milk. Use only if clearly needed and the potential benefit justifies the potential risk to the infant, and only after consulting a physician.

Before starting Ovestin, a complete medical and family history should be taken, including a general and gynaecological examination.

• Use with caution in patients with a history of migraine, hypertension, gallbladder disease, or risk factors for thromboembolic or cardiovascular disease; these patients require closer monitoring.
• Periodic medical and breast/gynaecological examinations are recommended during prolonged treatment with Ovestin.
• Treatment should be stopped immediately and medical advice sought if jaundice or deterioration in liver function occurs, if blood pressure rises significantly, if a first migraine-type headache occurs, or if signs of thromboembolism (leg pain/swelling, chest pain, breathlessness) appear.
• Ovestin is not recommended for use in women with a personal history of breast cancer or estrogen-dependent tumours (see Contraindications).
• Systemic absorption, while lower with vaginal use than with oral use, still occurs, so the same class-related precautions for estrogens apply, particularly with prolonged or high-dose therapy.

Acute overdose with Ovestin is unlikely to be life-threatening. Possible features of overdose include nausea, vomiting, breast tenderness, abdominal discomfort, drowsiness, and withdrawal bleeding in women. There is no specific antidote.

In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment should be symptomatic and supportive, provided under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Ovestin is contraindicated in patients with severe hepatic impairment or active liver disease (see Contraindications); use with caution and close monitoring in milder hepatic conditions.

Renal impairment: No specific dose adjustment is well established; use with caution and physician judgment, as there is limited formal data.

Elderly: Ovestin is primarily used in postmenopausal women; use the lowest effective dose and monitor regularly for cardiovascular and thromboembolic risk factors.

Children: Ovestin is not indicated for use in children; safety and efficacy in the pediatric population have not been established.

Ovestin should be used at the lowest effective dose for the shortest duration consistent with the treatment goals. For vaginal atrophy, an initial course of 2–3 weeks is typically followed by a reduced maintenance regimen, which may be continued longer term under medical supervision because systemic exposure with vaginal use is comparatively low. For peri-procedural use (before surgery or a Pap smear), treatment is short-course only. Treatment duration and continued need should be reviewed periodically (e.g., annually) by the prescribing physician.

Estrogens; Natural steroidal estrogens; Topical/systemic hormone replacement therapy agents

Estriol is a weak, short-acting agonist at estrogen receptors ERα and ERβ, restoring vaginal and urethral epithelial integrity, vaginal blood flow, lubrication, and normal vaginal pH/flora in estrogen-deficient postmenopausal women.

X

Ovestin is not indicated for use in children or adolescents. Safety and efficacy in the pediatric population have not been established, and it should not be used in this group outside of specialist/research settings.